Matricelf Nears Human Trials for Personalized Spinal Cord Injury Cure

PHOENIX, AZ – February 26, 2026 – Israeli regenerative medicine company Matricelf is set to showcase its pioneering spinal cord injury (SCI) therapy at the Digital Spine & Pain Neuroscience Summit (DSPN) this week, a move that signals its accelerating push toward first-in-human clinical trials in the United States. The company's attendance at the premier global gathering for spine care experts comes at a critical juncture, as it transitions from years of promising preclinical research to the precipice of clinical application, offering a potential paradigm shift for patients with paralysis.

Matricelf is developing a highly personalized treatment that engineers 3D neural implants from a patient's own cells. This autologous approach aims to regenerate damaged spinal cord tissue and restore lost function, a goal that has remained elusive for decades. As the company’s senior team engages with global neuroscience leaders in Phoenix, the focus is firmly on its clinical development strategy and the search for strategic partners to bring this complex therapy from the laboratory to patients.

A New Frontier in Regenerative Medicine

At the heart of Matricelf’s strategy is a unique technology that circumvents the primary challenges of regenerative medicine: immune rejection and tissue integration. The process begins by taking a small sample of a patient's own tissue, from which induced pluripotent stem cells (iPSCs) and an extracellular matrix are derived. These components are then used to bio-engineer a functional 3D neural implant that is genetically identical to the patient.

This "from the patient, for the patient" methodology is designed to create a one-time, curative solution that the body will not reject. Preclinical data has provided a compelling foundation for this optimism. In a key efficacy trial in rats with spinal cord injuries, completed in late 2024, the therapy demonstrated significant functional recovery. Animals treated with Matricelf's implant showed an average improvement on the FDA-recognized Basso, Beattie, and Bresnahan (BBB) motor function scale from a score of 2.5 post-injury to 9.1 after 12 weeks, a notable improvement over the control group's score of 8.5. These results were further validated using the advanced CatWalk XT gait analysis system.

Building on this success, the company is advancing a large-scale Good Laboratory Practice (GLP) compliant safety study, a crucial step for regulatory approval. With positive interim results already reported, the final data expected in the first half of this year will form a key part of the submission package for initiating human trials.

The Strategic Path to the Clinic

The DSPN Spine Summit provides an invaluable platform for Matricelf to articulate its vision as it prepares for this next chapter. The company aims to engage with key opinion leaders, explore strategic partnerships for clinical translation and commercialization, and highlight its recent milestones.

"We are pleased to participate in the DSPN Spine Summit, where leading clinicians and innovators will convene to advance the future of spine care," said Gil Hakim, CEO of Matricelf, in a statement. "This Summit is an invaluable opportunity to share our vision and engage with the global spine and neuroscience community as we move toward human clinical studies in the U.S."

This move is underpinned by significant regulatory progress in Israel. The company has already received Helsinki Committee approval for collecting blood samples from SCI patients and, more recently, gained preliminary approval from Israel's Ministry of Health to begin compassionate use trials in eight patients. This provides a clear, albeit initial, pathway to gather human data.

Matricelf has laid a robust operational groundwork for its clinical ambitions. An agreement is in place with Tel Aviv Sourasky Medical Center (Ichilov) to use dedicated clean rooms for GMP-compliant manufacturing of the implants. The company expects to begin identifying eligible patients during 2026, with the first clinical implantation targeted for 2027—a milestone that represents a major value inflection point for the company and the field.

Navigating a High-Stakes Market

Matricelf is entering a market defined by profound unmet need. Spinal cord injury affects millions worldwide, with no effective cure and an annual economic burden exceeding $40 billion in the United States alone. The global regenerative medicine market for SCI, valued at approximately $54 million in 2026, is projected to surge to $655 million by 2035, reflecting the intense demand for a breakthrough.

The company is targeting an initial annual market of $4 to $5 billion in the U.S., comprising adults with recent complete spinal cord injuries. While the proposed treatment cost of $1 million to $1.5 million is substantial, Matricelf frames it as a one-time curative expense that could offset the immense lifelong costs of chronic care and disability. This value proposition will be central to securing reimbursement and driving adoption if clinical trials prove successful.

While the competitive landscape includes major medical device and pharmaceutical players like Medtronic and Boston Scientific, Matricelf’s focus on structural regeneration—repairing the cord itself—differentiates it from therapies that manage symptoms or provide functional support.

Building a Foundation for Growth

To fund its ambitious clinical program, Matricelf has actively shored up its financial position. In 2025, it completed a private placement of approximately NIS 24.4 million (around $6.6 million), strengthening its balance sheet for the transition to the clinical stage. The company has also bolstered its leadership, appointing Ron Miron, former CEO of Teva Israel, as active Chairman of the Board to guide its next phase of growth.

Looking ahead, Matricelf has initiated a preliminary evaluation for a potential Nasdaq listing, targeting a 2027 window to access a broader international investor base. This forward-looking strategy extends to its technology platform as well. The company recently announced a memorandum of understanding to form a subsidiary, NeuroVectis, which will leverage Matricelf’s platform to develop a treatment for Parkinson's disease. This move not only diversifies its pipeline but also validates the broader potential of its core tissue-engineering technology.

As Matricelf stands before the global spine community in Phoenix, it represents more than just a single company's progress. It embodies the collective hope for a future where paralysis from spinal cord injury is no longer a permanent sentence.